418 related articles for article (PubMed ID: 32575941)
1. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
2. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract][Full Text] [Related]
5. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
[TBL] [Abstract][Full Text] [Related]
6. Expression of NIS, VEGF-A and Thyroid Autoantibody in Papillary Thyroid Carcinoma with or without Hashimoto's Disease.
Ma Y; He J; Shen N; Guo R
ORL J Otorhinolaryngol Relat Spec; 2019; 81(5-6):281-286. PubMed ID: 31480047
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.
Kim KH; Suh KS; Kang DW; Kang DY
Pathol Int; 2005 Sep; 55(9):540-5. PubMed ID: 16143028
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
9. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].
Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY
Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653
[No Abstract] [Full Text] [Related]
10. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population.
Kang DY; Kim KH; Kim JM; Kim SH; Kim JY; Baik HW; Kim YS
Thyroid; 2007 Nov; 17(11):1031-8. PubMed ID: 17900235
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis.
Mohamed SY; Ibrahim TR; Elbasateeny SS; Abdelaziz LA; Farouk S; Yassin MA; Embaby A
Sci Rep; 2020 Jun; 10(1):10651. PubMed ID: 32606302
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.
Janicki L; Patel A; Jendrzejewski J; Hellmann A
Front Endocrinol (Lausanne); 2023; 14():1273498. PubMed ID: 38047109
[TBL] [Abstract][Full Text] [Related]
14. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis.
Zhang Q; Liu BJ; Ren WW; He YP; Li XL; Zhao CK; Zhang YF; Yue WW; Zheng JY; Xu HX
Sci Rep; 2017 Jul; 7(1):4899. PubMed ID: 28687736
[TBL] [Abstract][Full Text] [Related]
15. Interaction of BANCR in the relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma expression patterns and possible molecular mechanisms.
Zhang J; Yao L; Guo Y
J Gene Med; 2024 Feb; 26(2):e3663. PubMed ID: 38342961
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto's thyroiditis lymphocytic infiltration is present.
Marotta V; Guerra A; Zatelli MC; Uberti ED; Di Stasi V; Faggiano A; Colao A; Vitale M
Clin Endocrinol (Oxf); 2013 Nov; 79(5):733-8. PubMed ID: 23469895
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Pathological Characteristics of Patients With Papillary Thyroid Carcinoma Coexisting With Hashimoto's Thyroiditis: A Retrospective Cohort Study.
Yang Y; Liu J; Shi X; Wang M
Cancer Control; 2023; 30():10732748231199647. PubMed ID: 37643366
[TBL] [Abstract][Full Text] [Related]
18. Papillary thyroid cancer with Hashimoto's thyroiditis attenuates the tumour aggressiveness through the up-regulation of E-cadherin and TGF-β expression.
Kim SJ; Lee SE; Kim YI; Nam-Goong IS; Jung HW; Kim ES
Clin Exp Med; 2023 Jul; 23(3):833-840. PubMed ID: 35871446
[TBL] [Abstract][Full Text] [Related]
19. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
20. Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.
Liu X; Liu H; Wang L; Han Y; Kong L; Zhang X
Diagn Pathol; 2024 Feb; 19(1):29. PubMed ID: 38341587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
